Chapel Hill, NCNCT06242795Now EnrollingIRB Ready

Bronchiectasis Clinical Trial in Chapel Hill, NC

Access cutting-edge bronchiectasis treatment through this clinical trial at a research site in Chapel Hill. Study-provided care at no cost to qualified participants.

Sponsored by University of North Carolina, Chapel Hill

Quick Self-Assessment

See if you qualify for this Chapel Hill location

Preparing your pre-screening questions…

Expert Care in Chapel Hill

Access bronchiectasis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related bronchiectasis treatment provided free

Apply for This Chapel Hill Location

Check if you qualify for this bronchiectasis clinical trial in Chapel Hill, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chapel Hill

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chapel Hill site if eligible
  4. 4Begin participation

About This Bronchiectasis Study in Chapel Hill

The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a person's lungs can clear inhaled particles will be assessed at baseline, and after acute (single dose) HS treatment, as well as after two weeks of treatment with HS. The study has two main questions: 1. Evaluate the repeatability MCC measures in people with non-CF bronchiectasis 2. Compare MCC at baseline (before treatment with HS), after a single dose of HS (acute effect of HS), and after two weeks of treatment with HS twice a day (sustained effect of HS). Participants will participate in up to 5 study visits if completing both Aim 1 and Aim 2: 1 screening/enrollment visit, 2 baseline visits (1 baseline visit if only participating in Aim 2), 1 visit during which first dose of HS would be administered and assessed, and 1 visit after 2 weeks of treatment with HS.

Sponsor: University of North Carolina, Chapel Hill

Who Can Participate

Inclusion Criteria

Adults \>18 years of age able to provide informed consent
Diagnosis of bronchiectasis confirmed on prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung
Forced expiratory volume in one second (FEV1) % predicted \> 40%, inclusive
History of prior bronchiectasis exacerbations (requiring antibiotics)
Chronic cough

Exclusion Criteria

Diagnosis of cystic fibrosis (CF), primary ciliary dyskinesia (PCD), chronic aspiration, or predominantly traction bronchiectasis due to interstitial lung disease (ILD)
Unable or unwilling to undergo HS washout period of 2 weeks preceding first baseline MCC scan
Concomitant inhaled acetylcysteine or dornase alfa use
Recent pulmonary exacerbation in preceding 4 weeks
History of intolerance to HS (bronchospasm, hemoptysis)
History of significant hemoptysis (\>60 ml) within the preceding 3 months
Chronic supplemental oxygen use at rest
Severe asthma, as reflected by need for chronic oral corticosteroids (\>10mg/day), asthma biologic therapies, hospitalization for status asthmaticus within the past year, or bronchiectasis felt to have resulted from chronic asthma
Significant bronchodilator response (\>15% increase in FEV1 or forced vital capacity \[FVC\]) on pre-post spirometry testing during screening visit
Failed HS tolerability test (HSTT) at screening, as indicated by:
Intolerable symptoms after HS administration
Decline in FEV1 % predicted by \>20% when measured 15 min after HS administration
Decline in FEV1 % predicted between 10-20% when measured at 15 min that does not recover to within 10% of baseline without intervention 1 hour post HS test dose
Smoking/vaping, any substance within the past year, or \>10 pack-years of cigarette use over their lifetime
More than 2 chest CTs in the past year or a combination of procedures believed to have exposed the lungs to \>150 millisieverts (mSv)
Current/recent participation in other interventional studies for NCFB, allowing for appropriate wash-out time

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chapel Hill?

Yes, this clinical trial (NCT06242795) has an active research site in Chapel Hill, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Bronchiectasis Treatment Options in Chapel Hill, NC

If you're searching for bronchiectasis treatment options in Chapel Hill, NC, this clinical trial (NCT06242795) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chapel Hill research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bronchiectasis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all bronchiectasis clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Chapel Hill, NC

See all ankylosing spondylitis clinical trials recruiting in Chapel Hill — not just this study.

Browse Ankylosing Spondylitis Trials in Chapel Hill →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsBronchiectasis TrialsAll Conditions →

Ready to Join in Chapel Hill?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chapel Hill, NC